A director at L'Oreal sold 10,000 shares at 440.894EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, CAF, CELLNEX, FERROVIAL, IBERDROLA, ROVI. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 1Q’24 results to be released over the coming days in Spain. Results and macro data drag down stock markets After three straight days of gains, the business results and the macro data in the US led to stock market losses on both sides of the Atlanti...
>Agreement to manufacture pre-filled syringes for a global pharma company - Rovi has announced that its subsidiary ROIS has entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company. Under the terms of the agreement, ROIS will provide a high-speed production line at its San Sebastián de los Reyes facility, with an estimated annual capacity of 100 million units. The agreement includes the technology transfer for ase...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, CAF, CELLNEX, IBERDROLA, FERROVIAL, ROVI. EUROPA: AIRBUS, DEUTSCHE TELEKOM, SAFRAN, VINCI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. Los resultados y la macro lastran las bolsas Tras tres días de ganancias, los r...
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
>Giovanni Di Napoli to be group CEO - Cosmo Pharmaceuticals this morning announced the appointment of Giovanni Di Napoli as CEO, to replace Alessandro Della Chà. The appointment takes effect at the AGM scheduled for 24 May. This appointment follows the Capital Market Day in March which set out the next stages for the company and its ambitions. Mr Di Napoli is very familiar with the GI Genius platform, coming from Medtronic where he occupied several management pos...
>Mr Di Napoli devient CEO du groupe - Cosmo Pharmaceuticals annonce ce matin la nomination de Giovanni Di Napoli au poste de CEO, en remplacement d’Alessandro Della Chà. Cette nomination sera effective lors de l’AGM prévu le 24 mai prochain. Cette nomination fait suite à son Capital Market Day réalisé en mars dernier exposant les prochaines étapes de la société et ses ambitions. Mr Di Napoli connait bien la plateforme GI Genius car vient de Medtronic où il a occ...
>Slower growth over the coming quarters? - Highlights from yesterday’s meeting:1/ Q1 was a good quarter, but growth in Q1 (+13% cc) seems unlikely to be extrapolated: i/ new generic versions of Somatuline are set to reach Europe and North America in H2 2024/early 2025, ii/ Cabometyx benefited from a cut-off effect, resulting in a favourable cumulative impact of =€ 20me in Q1.Management remains optimistic about Dysport (market share gains and indication exten...
>Moindre croissance sur les prochains trimestres ? - De la réunion d’hier, nous retenons que :1/ T1 a été bon mais la croissance du T1 (+13% à tcc.) ne semble pas extrapolable : i/ de nouveaux génériques de Somatuline devraient arriver en Europe et en Amérique du Nord au S2 2024/début 2025, ii/ Cabometyx a bénéficié d’un effet de cut-off, soit un impact favorable cumulé de =20 M€e, au T1.La Direction s’est montrée toujours optimiste pour Dysport (prise de Pd...
HONOLULU--(BUSINESS WIRE)-- Central Pacific Financial Corp. (NYSE: CPF) (the "Company"), parent company of Central Pacific Bank (the "Bank" or "CPB"), today reported net income of $12.9 million, or fully diluted earnings per share ("EPS") of $0.48 for the first quarter of 2024, compared to net income of $14.9 million, or EPS of $0.55 in the previous quarter and net income of $16.2 million, or EPS of $0.60 in the year-ago quarter. "Our financial results for the first quarter reflect our continued focus on optimizing the balance sheet, while maintaining strong liquidity, asset quality and capi...
>Q1 2024 sales: +13.3%: a good organic level - Q1 2024 sales were € 822.4m, +10.9% (+13.3% cc.) with sales in oncology up +7.5% cc, rare diseases +69% cc (although with the entry into the scope of consolidation of Sohonos) and neuroscience at +19.6% cc.Forex had an impact of close to -2.5% in Q1.The group reaffirmed its guidance (growth of 6% cc and an operating margin of around 30%).The main franchises are solid - New products faring well - §sep...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.